Luxen A - Search Results

1

Aptamers as radiopharmaceuticals for nuclear imaging and therapy.

Gijs M, Aerts A, Impens N, Baatout S, Luxen A. Gijs M, et al. Among authors: luxen a. Nucl Med Biol. 2016 Apr;43(4):253-71. doi: 10.1016/j.nucmedbio.2015.09.005. Epub 2015 Sep 28. Nucl Med Biol. 2016. PMID: 26746572 Review.

2

Radiochemical synthesis and tissue distribution of p-[18F]DMPPF, a new 5-HT1A ligand for PET, in rats.

Defraiteur C, Lemaire C, Luxen A, Plenevaux A. Defraiteur C, et al. Among authors: luxen a. Nucl Med Biol. 2006 Jul;33(5):667-75. doi: 10.1016/j.nucmedbio.2006.03.010. Epub 2006 Jun 12. Nucl Med Biol. 2006. PMID: 16843842

3

Biological carrier molecules of radiopharmaceuticals for molecular cancer imaging and targeted cancer therapy.

Aerts A, Impens NR, Gijs M, D'Huyvetter M, Vanmarcke H, Ponsard B, Lahoutte T, Luxen A, Baatout S. Aerts A, et al. Among authors: luxen a. Curr Pharm Des. 2014;20(32):5218-44. doi: 10.2174/1381612819666140110114902. Curr Pharm Des. 2014. PMID: 24606796 Review.

4

Gallium-68-labelled NOTA-oligonucleotides: an optimized method for their preparation.

Gijs M, Dammicco S, Warnier C, Aerts A, Impens NR, D'Huyvetter M, Léonard M, Baatout S, Luxen A. Gijs M, et al. Among authors: luxen a. J Labelled Comp Radiopharm. 2016 Feb;59(2):63-71. doi: 10.1002/jlcr.3363. Epub 2015 Dec 29. J Labelled Comp Radiopharm. 2016. PMID: 26712111

5

Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive Cancer.

Gijs M, Penner G, Blackler GB, Impens NR, Baatout S, Luxen A, Aerts AM. Gijs M, et al. Among authors: luxen a. Pharmaceuticals (Basel). 2016 May 19;9(2):29. doi: 10.3390/ph9020029. Pharmaceuticals (Basel). 2016. PMID: 27213406 Free PMC article.

6

Fully automated radiosynthesis of N(1)-[(18)F]fluoroethyl-tryptophan and study of its biological activity as a new potential substrate for indoleamine 2,3-dioxygenase PET imaging.

Henrottin J, Lemaire C, Egrise D, Zervosen A, Van den Eynde B, Plenevaux A, Franci X, Goldman S, Luxen A. Henrottin J, et al. Among authors: luxen a. Nucl Med Biol. 2016 Jun;43(6):379-89. doi: 10.1016/j.nucmedbio.2016.03.001. Epub 2016 Mar 11. Nucl Med Biol. 2016. PMID: 27260779

7

Regiospecific radiolabelling of Nanofitin on Ni magnetic beads with [¹⁸F]FBEM and in vivo PET studies.

Dammicco S, Goux M, Lemaire C, Becker G, Bahri MA, Plenevaux A, Cinier M, Luxen A. Dammicco S, et al. Among authors: luxen a. Nucl Med Biol. 2017 Aug;51:33-39. doi: 10.1016/j.nucmedbio.2017.04.006. Epub 2017 Apr 27. Nucl Med Biol. 2017. PMID: 28575696

8

Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.

Hustinx R, Lemaire C, Jerusalem G, Moreau P, Cataldo D, Duysinx B, Aerts J, Fassotte MF, Foidart J, Luxen A. Hustinx R, et al. Among authors: luxen a. J Nucl Med. 2003 Apr;44(4):533-9. J Nucl Med. 2003. PMID: 12679396 Free article. Clinical Trial.

9

NEMA NU4-2008 image quality performance report for the microPET focus 120 and for various transmission and reconstruction methods.

Bahri MA, Plenevaux A, Warnock G, Luxen A, Seret A. Bahri MA, et al. Among authors: luxen a. J Nucl Med. 2009 Oct;50(10):1730-8. doi: 10.2967/jnumed.109.063974. Epub 2009 Sep 16. J Nucl Med. 2009. PMID: 19759103 Free article.

10

Production at the Curie level of no-carrier-added 6-18F-fluoro-L-dopa.

Libert LC, Franci X, Plenevaux AR, Ooi T, Maruoka K, Luxen AJ, Lemaire CF. Libert LC, et al. J Nucl Med. 2013 Jul;54(7):1154-61. doi: 10.2967/jnumed.112.112284. Epub 2013 May 8. J Nucl Med. 2013. PMID: 23658219 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

255 results

Search Page

Filters